2D-QSAR Studies on Unsaturated 4-Azasteroids as 5α-reductase Inhibitors

Authors

  • Neelima Dhingra Department of Pharmaceutical Chemistry, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India
  • Priyanka Rana Department of Pharmaceutical Chemistry, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India
  • Richa Dhingra Department of Pharmaceutical Chemistry, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India
  • Monika . Department of Pharmaceutical Chemistry, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India

Abstract

Dihydrotestosterone (DHT) a major circulating male hormone is produced by NADPH dependent enzyme 5α-reductase (5 alpha R) and has been found to be causative agent in the development of pathological condition i.e. benign prostate hyperplasia (BPH). Thus inhibition of 5α-reductase enzyme represents a novel target in the treatment of BPH. Present study describes the relationship between the 5α-Reductase inhibitory activity for structurally related unsaturated 4-azasteroids derivatives and their physicochemical descriptors in quantitative terms. Using Vlife molecular design suits (MDS), LOO validated 2D-QSAR model has been developed with statistical data r2 = 0.8706, q2 =0.7122 , F = 14.5758, pred r2 = 0.7441. Descriptor with positive and negative correlation with the biological activity has been highlighted. This validated 2D-QSAR model may be used to design 5α-Reductase derivatives with better inhibitory properties.

 

Keywords: Dihydrotestosterone, benign prostatic hyperplasia, 5α-reductase inhibitors, 2D-QSAR, regression analysis, 4-azasteroids

Cite this Article

Priyanka Rana, Richa Dhingra, Monika et al. 2D-QSAR Studies on Unsaturated 4-Azasteroids as 5α-Reductase Inhibitors. Research & Reviews: A Journal of Drug Design & Discovery. 2017; 4(1): 26–37p.

Downloads

Published

2019-03-04

Issue

Vol. 4 No. 1 (2017)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.